SCHEMBL5481825

SCHEMBL5481825

COc1cc2c(cc1OC)[C@H]1C[C@H](O)CC[C@H]1N=C2c1ccc(C(=O)N2CCN(CC(=O)N(C)C)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.50
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
F10 P00742 1/20 0.44
CDK9 P50750 6/20 0.38
CCNT1 O60563 4/20 0.38
TLR9 Q9NR96 3/20 0.38
TLR8 Q9NR97 3/20 0.38
TLR7 Q9NYK1 3/20 0.38
POLB P06746 2/20 0.38
DRD3 P35462 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CASP3 P42574 1/20 0.36
CASP7 P55210 1/20 0.36
HTT P42858 1/20 0.36
CYP2C19 P33261 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473283 0.95 PDE4D (0.48) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5056407 0.90 PDE4D (0.52) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5479644 0.89 PDE4D (0.45) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5476149 0.87 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5480188 0.87 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CTLR9
SCHEMBL5056730 0.86 PDE4D (0.49) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5481979 0.85 PDE4D (0.46) PDE4DPDE4APDE4BPDE4CPOLB
SCHEMBL5479675 0.84 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CPOLB
SCHEMBL5477909 0.84 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CF10
SCHEMBL5479779 0.83 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CDRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US claimed
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US disclosed
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.